Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk

Abstract Background People with HIV have an increased cardiovascular disease (CVD) risk due to both HIV and adverse effects of treatments. The currently preferred class of anti-retroviral drugs, integrase strand transfer inhibitors (INSTIs), has variably been linked to higher CVD risk and weight gai...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Phyo Pyae Nyein, Hila Haskelberg, Marianne Martinello, Margaret Lowe, David Goodman-Meza, Anchalee Avihingsanon, Anthony D. Kelleher, Anthony Rodgers, Aletta E. Schutte, Eriobu Chukwudalu Nnakelu, Helen Byakwaga, Janine Trevillyan, Marcelo Losso, Nagalingeswaran Kumarasamy, Raja Iskandar Shah Raja Azwa, Richard Kaplan, Brent Clifton, Clare Arnott, Nila J. Dharan, Kathy Petoumenos, Gail V. Matthews
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2026-04-01
Schriftenreihe:	Trials
Schlagworte:	HIV SGLT2i Dapagliflozin Dolutegravir HIV integrase inhibitors Pitavastatin
Online-Zugang:	https://doi.org/10.1186/s13063-026-09723-2
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!